| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
REVENUES | ||||||
Real property rental | ||||||
1,155 | 1,121 | 828 | 0 | - | ||
Medical related consulting services - related party | ||||||
355 | 269 | 222 | - | - | ||
Medical related consulting services - related party | ||||||
- | - | - | 616 | - | ||
Development services and sales of developed products | ||||||
35 | 171 | 26 | 0 | - | ||
Total Revenues | ||||||
1,546 | 1,562 | 1,077 | 616 | 0 | ||
COSTS AND EXPENSES | ||||||
Real property operating expenses | ||||||
818 | 793 | 542 | 0 | - | ||
Medical related consulting services - related party | ||||||
284 | 250 | 272 | 73 | - | ||
Development services and sales of developed products | ||||||
103 | 130 | 15 | 0 | - | ||
Total Costs and Expenses | ||||||
1,206 | 1,174 | 829 | 73 | - | ||
REAL PROPERTY OPERATING INCOME | ||||||
-337 | -327 | -286 | 0 | - | ||
GROSS PROFIT FROM MEDICAL RELATED CONSULTING SERVICES | ||||||
71 | 18 | - | - | - | ||
GROSS LOSS FROM DEVELOPMENT SERVICES AND SALES OF DEVELOPED PRODUCTS | ||||||
-68 | 41 | 11 | 0 | - | ||
Total Gross Profit | ||||||
339 | 388 | 49 | -543 | - | ||
OTHER OPERATING EXPENSES: | ||||||
Professional fees | ||||||
- | - | 1,033 | 395 | - | ||
Selling expenses | ||||||
- | - | 15 | 6 | - | ||
Compensation and related benefits | ||||||
8,743 | 2,715 | 1,291 | 10 | - | ||
Research and development expenses | ||||||
1,781 | 39 | - | - | - | ||
Other general and administrative | ||||||
8,181 | 5,264 | 464 | 53 | - | ||
Impairment loss | ||||||
1,010 | - | - | - | - | ||
Impairment loss | ||||||
- | - | 1,321 | 0 | - | ||
GENERAL AND ADMINISTRATIVE EXPENSES | ||||||
- | - | - | - | 31 | ||
Total Other Operating Expenses | ||||||
19,717 | 8,019 | 4,125 | 466 | 31 | ||
LOSS FROM OPERATIONS | ||||||
-19,377 | -7,631 | -3,877 | 76 | -31 | ||
OTHER INCOME (EXPENSE) | ||||||
Interest income | ||||||
- | - | 1 | 0 | - | ||
Interest expense | ||||||
33 | 314 | 138 | 0 | - | ||
Interest expense - related party | ||||||
49 | - | - | - | - | ||
Change in fair value of warrants liabilities | ||||||
2,817 | - | - | - | - | ||
Financing expense | ||||||
-525 | - | - | - | - | ||
Grant income | ||||||
- | - | 22 | - | - | ||
Loss from equity-method investment | ||||||
-55 | -52 | - | - | - | ||
Foreign currency transaction gain (loss) | ||||||
12 | -106 | -57 | 0 | - | ||
Loss from noncontrolling interest deficit adjustment | ||||||
-862 | - | - | - | - | ||
Grant income | ||||||
- | - | - | 0 | - | ||
Other income | ||||||
3 | 53 | - | 0 | - | ||
Total Other Expense, net | ||||||
1,307 | -421 | -171 | - | - | ||
LOSS BEFORE INCOME TAXES | ||||||
-18,070 | -8,052 | -4,049 | 77 | - | ||
OTHER INCOME (EXPENSE) | ||||||
- | - | - | - | 0 | ||
INCOME TAXES | ||||||
- | - | - | 21 | 0 | ||
NET LOSS | ||||||
-18,070 | -8,052 | -4,049 | 55 | -31 | ||
LESS: NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | ||||||
- | -278 | -585 | 0 | - | ||
NET LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | ||||||
-18,070 | -7,774 | -3,464 | 55 | - | ||
COMPREHENSIVE LOSS: | ||||||
NET LOSS | ||||||
-18,070 | -8,052 | -4,049 | 55 | - | ||
OTHER COMPREHENSIVE (LOSS) INCOME | ||||||
Unrealized foreign currency translation (loss) gain | ||||||
-20 | -143 | 2 | -94 | - | ||
COMPREHENSIVE LOSS | ||||||
-18,091 | -8,195 | -4,047 | -38 | - | ||
LESS: COMPREHENSIVE LOSS ATTRIBUTABLE TO NON-CONTROLLING INTEREST | ||||||
- | -276 | -585 | 0 | - | ||
COMPREHENSIVE LOSS ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS | ||||||
-18,091 | -7,918 | -3,461 | -38 | - | ||
NET LOSS PER COMMON SHARE ATTRIBUTABLE TO AVALON GLOBOCARE CORP. COMMON SHAREHOLDERS: | ||||||
Basic and diluted | ||||||
-0.24 | -0.11 | -0.05 | 0.00 | - | ||
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: | ||||||
(Loss) per common share - Basic and Diluted | ||||||
- | - | - | - | 0.00 | ||
Basic and diluted | ||||||
75,116 | 72,004 | 65,033 | 51,139 | 6,334 | ||